• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Introduction to Tert-butyl N-(4-hydroxybut-2-yn-1-yl)carbamate (CAS No. 214749-90-3)

Tert-butyl N-(4-hydroxybut-2-yn-1-yl)carbamate, identified by its Chemical Abstracts Service (CAS) number 214749-90-3, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic synthesis. This compound belongs to the class of carbamates, which are widely recognized for their versatile applications in medicinal chemistry, particularly as intermediates in the synthesis of biologically active molecules. The unique structural features of Tert-butyl N-(4-hydroxybut-2-yn-1-yl)carbamate, including the presence of a terminal alkyne group and a hydroxyl-substituted butyl chain, make it a valuable building block for the development of novel therapeutic agents.

The molecular structure of Tert-butyl N-(4-hydroxybut-2-yn-1-yl)carbamate can be described as a carbamate moiety linked to a tert-butyl group, with a 4-hydroxybut-2-yn-1-yl side chain. This arrangement imparts distinct chemical properties that are conducive to further functionalization, making it an attractive candidate for synthetic chemists. The carbamate group, characterized by its high reactivity, facilitates various transformations such as nucleophilic substitution and coupling reactions, while the terminal alkyne functionality provides opportunities for further elaboration through cross-coupling reactions like Suzuki-Miyaura or Sonogashira couplings.

In recent years, there has been a growing interest in the development of carbamate-based compounds due to their potential pharmacological properties. Carbamates have been explored as inhibitors of enzymes involved in metabolic pathways relevant to diseases such as cancer, diabetes, and neurodegenerative disorders. The hydroxyl group in Tert-butyl N-(4-hydroxybut-2-yn-1-yl)carbamate adds an additional layer of reactivity, enabling the formation of hydrogen bonds and influencing the compound's solubility and binding affinity to biological targets. These characteristics make it a promising candidate for further investigation in drug discovery.

One of the most compelling aspects of Tert-butyl N-(4-hydroxybut-2-yn-1-yl)carbamate is its utility as a precursor in the synthesis of more complex molecules. The tert-butyl group provides steric hindrance, which can be advantageous in designing molecules with specific binding profiles. Additionally, the alkyne functionality allows for the introduction of diverse substituents through metal-catalyzed reactions, enabling the construction of intricate scaffolds. These features have made this compound a focal point in synthetic organic chemistry and medicinal chemistry research.

Recent studies have highlighted the importance of Tert-butyl N-(4-hydroxybut-2-yn-1-yl)carbamate in the development of novel therapeutics. For instance, researchers have utilized this compound as an intermediate in the synthesis of small-molecule inhibitors targeting protein-protein interactions implicated in various diseases. The ability to modify both the carbamate and alkyne functionalities allows for fine-tuning of physicochemical properties such as solubility, permeability, and metabolic stability, which are critical factors in drug design. Furthermore, the hydroxyl group can be exploited to introduce additional functional moieties that enhance binding affinity or modulate pharmacokinetic profiles.

The pharmaceutical industry has also shown interest in Tert-butyl N-(4-hydroxybut-2-yn-1-yl)carbamate due to its potential as a scaffold for drug discovery programs. Its structural versatility makes it suitable for generating libraries of compounds that can be screened for biological activity. High-throughput screening (HTS) campaigns have been conducted using derivatives of this compound to identify lead candidates for further optimization. The results from these screenings have provided valuable insights into the pharmacological properties of carbamate-based molecules and have paved the way for new therapeutic approaches.

From a synthetic chemistry perspective, Tert-butyl N-(4-hydroxybut-2-yn-1-yI)carbamate exemplifies the importance of functional group interplay in designing versatile building blocks. The combination of a reactive carbamate group and an alkyne moiety offers numerous possibilities for further chemical manipulation. Advances in catalytic methods have further expanded the synthetic toolkit available for modifying this compound, enabling access to a wide range of derivatives with tailored properties. These advancements underscore the significance of Tert-butyl N-(4-hydroxybut-ylnl)-yI]carbamate as a cornerstone in modern synthetic organic chemistry.

The future prospects for Tert-butyl N-(4-hydroxybut-ylnl)-yI]carbamate are promising, with ongoing research exploring its potential applications in various fields. As our understanding of biological pathways continues to expand, so does the demand for innovative molecular tools to modulate these pathways effectively. Compounds like Tert-butyl N-(4-hydroxybut-ylnl)-yI]carbamate, with their unique structural features and reactivity profiles, are poised to play a crucial role in addressing unmet medical needs.

• 92136-39-5(Boc-Propargylamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)